Earnings ·
IN8bio reports Q3 net loss of $4.6M and appoints Oxana Polyakova as SVP R&D
INABIN8Bio, Inc.
IN8bio reported a third-quarter 2026 net loss of $4.6 million, or $0.24 per share, compared to a $3.9 million loss in the prior year period. Research and development expenses increased to $2.6 million from $2.1 million due to preclinical costs for its T cell engager platform, while general and administrative expenses rose to $2.1 million from $1.9 million. The company ended the quarter with $14.0 million in cash. Additionally, IN8bio appointed Oxana Polyakova as Senior Vice President of Research & Development to lead efforts on its gamma-delta T cell engager pipeline. IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies and engagers for cancer and autoimmune diseases.